Association between gestational age at birth, antenatal corticosteroids, and outcomes at 5 years: multiple courses of antenatal corticosteroids for preterm birth study at 5 years of age (MACS-5)

作者：Asztalos Elizabeth^*; Willan Andrew; Murphy Kellie; Matthews Stephen; Ohlsson Arne; Saigal Saroj; Armson Anthony; Kelly Edmond; Delisle Marie France; Gafni Amiram; Lee Shoo; Sananes Renee; Rovet Joanne; Guselle Patricia; Amankwah Kofi

来源：BMC Pregnancy and Childbirth, 2014, 14(1): 272.

DOI：10.1186/1471-2393-14-272

• Preterm birth
• Long-term neurodevelopmental outcomes
• Antenatal corticosteroids
• Gestational age at birth

Background: The Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study (MACS) showed no benefit in the reduction of major neonatal mortality/morbidity or neurodevelopment at 2 and 5 years of age. Using the data from the randomized controlled trial and its follow-up, the aim of this study was to evaluate the association between gestational ages at birth in children exposed to single versus multiple courses of antenatal corticosteroid (ACS) therapy in utero and outcomes at 5 years of age. %26lt;br%26gt;Method: A total of 1719 children, with the breakdown into groupings of %26lt; 30, 30-36, and %26gt;= 37 weeks gestation at birth, contributed to the primary outcome: death or survival with a disability in one of the following domains: neuromotor, neurosensory, and neurobehavioral/emotional disability and were included in this analysis. %26lt;br%26gt;Results: Gestational age at birth was strongly associated with the primary outcome, p %26lt; 0.001. Overall, the interaction between ACS groups and gestational age at birth was not significant, p = 0.064. Specifically, in the 2 preterm categories, there was no difference in the primary outcome between single vs. multiple ACS therapy. However, for infants born %26gt;= 37 weeks gestation, there was a statistically significant increase in the risk of the primary outcome in multiple ACS therapy, 48/213 (22.5%) compared to 38/249 (15.3%) in the single ACS therapy; OR = 1.69 [95% CI: 1.04, 2.77]; p = 0.037. %26lt;br%26gt;Conclusion: Preterm birth (%26lt; 37 weeks gestation) remained the primary factor contributing to an adverse outcome regardless of the number of courses of ACS therapy. Children born %26gt;= 37 weeks and exposed to multiple ACS therapy may have an increased risk of neurodevelopmental/neurosensory impairment by 5 years of age. To optimize outcomes for infants/children, efforts in reducing the incidence of preterm birth should remain the primary focus in perinatal research.

• 出版日期2014-8-13